FineHeart, a preclinical medical device company that has developed an implantable cardiac output management system designed to address the unmet need of patients suffering from severe heart failure, announced the successful completion of a €15 million funding round. This enables FineHeart to prepare for First-In-Human clinical trials planned for 2022.

Written by

Investors

Verve Event Zurich Investors

Our sophisticated investors include visionary family offices, leading wealth managers, institutions, founders, and senior executives. These individuals and organizations are all committed to shaping the next generation of innovation.

Learn more

Privacy Preference Center